Books.org participates in affiliate programs including Bookshop.org and the Amazon Services LLC Associates Program. We may earn a commission from qualifying purchases made through links on this page, at no additional cost to you.
Overview
"While bioethicists may enjoy the most thorough appreciation of both the promise and perils of new biotechnologies, international corporations are in fact the entities generating these technologies and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, and why an ethical business is likely a successful one." "In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business and bioethical issues." Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists, regulatory affairs managers, and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda's peerless text provides a unique tool for understanding and addressing the ethical dilemmas confronting society in the 21st century.Synopsis
"There is a palpable need for business to explore the issues Dhanda raises. Guiding Icarus offers a flight plan."
-from the Foreword by Philip R. Reilly
Guiding ICARUS
Merging Bioethics with Corporate Interests
Rahul K. Dhanda
While bioethicists may enjoy the most thorough appreciation of both the promise and perils of new biotechnologies, international corporations are in fact the entities generating these technologies and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, and why an ethical business is likely a successful one.
The author develops a dialogue between bioethics and corporate interests by examining case studies of several hot-button issues, including:
* Genetically modified foods
* DNA data banking
* Personalized medicine
* Stem cell research
In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business and bioethical issues.
Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists, regulatory affairs managers, and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda's peerless text provides a unique tool for understanding and addressing the ethical dilemmas confronting society in the 21st century.
Booknews
Dhanda (Business Development Division, Interleukin Genetics) offers advice to biotechnology companies on avoiding bad publicity and expensive lawsuits in pursuit of profiting off DNA manipulation and other recent technologies. By adopting ethical considerations into their corporate strategies, companies will avoid the worst effects of the controversies over these technologies, argues Dhanda. Separate chapters focus on the controversies arising from genetically modified food, DNA data banking, personalized medicine, and stem cell research. Annotation c. Book News, Inc., Portland, OR (booknews.com)
Editorials
From The Critics
Dhanda (Business Development Division, Interleukin Genetics) offers advice to biotechnology companies on avoiding bad publicity and expensive lawsuits in pursuit of profiting off DNA manipulation and other recent technologies. By adopting ethical considerations into their corporate strategies, companies will avoid the worst effects of the controversies over these technologies, argues Dhanda. Separate chapters focus on the controversies arising from genetically modified food, DNA data banking, personalized medicine, and stem cell research. Annotation c. Book News, Inc., Portland, OR (booknews.com)From the Publisher
"...particularly useful to corporate biotech managers due to Dhanda's explanation of the issues and suggestions on how to engage the public...inherent value in this discourse is how Dhanda explains how an ethical biotech business is likely to be a successful one." (Genomics & Proteomics, May 2002)"useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, July 2002)
"...if you read The Economist you'll doubtless find this of interest..." (Focus, August 2002)
"...offers an insider's view on why a bridge is needed to merge bioethics with corporate needs...written for the general audience...is especially useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, Vol. 22, No. 13, July 2002)
"...lays out a blueprint for executives...focusing on four subjects..." (HBS (Harvard Business School) Working Knowledge, July 2002)
"This book should stimulate much useful discussion in the biotechnology industry...the author should be congratulated." (Nature Biotechnology, August 1, 2002)
"...a must read for those interested in understanding how bioethics can help industry develop ethically and socially responsible biotechnologies." (Canadian Medical Association Journal, August 20, 2002)
"Dhanda applies a case study approach to four timely topics: genetically modified foods, DNA databanking, personalized medicine, and stem cell research. In each case, Dhanda gives a very basic review of the science, discusses the potential benefits of the technology and the ethical issues, and then uses prominent corporate examples to raise relevant issues and draw lessons." (JAMA, January 22/29, 2003-Vol 289, No. 4)
"The time couldn’t be better for a book on the ethical issues associated with biotechnology...discussions...are clearly welcome and needed." (Journal of the American Medical Association, Vol. 289, No. 4, January 2003)
"…an interesting and useful resource for any industry insider…" (Chemistry & Industry)
“…an interesting and useful resource for any industry insider…”(Chemistry & Industry, 21 April 2003)